Healthcare watchdogs in both England and Germany officially rejected Bayer's (OTC:BAYR.Y) new cancer drug, Vitraki. The National Institute for Health and Care Excellence (NICE), a top English health regulator, announced on Friday it can't recommend the drug at its current price tag and said it simply isn't cost-efficient.

Germany's top drug assessment group, IQWiG, also rejected the drug, citing insufficient data. Although Bayer's drug has shown encouraging results so far, IQWiG rejected the drug because clinical trials didn't have a comparison group of people who didn't take Vitraki.

Medical person looking at tumors on multiple computer screens.

Image source: Getty Images.

Vitraki is what's known as a tumor-agnostic or tissue-agnostic therapy, which means that it attempts to treat cancer cells regardless of what type of cancer it is and where it appeared in the body. In Vitraki's case, the drug targets cancer cells that have a specific type of chromosome mutation known as an NTRK gene fusion, present in less than 1% of all patients with solid tumors.

What's Vitrakvi anyway?

While Vitrakvi's targeted demographic is a relatively narrow patient population, the company expected to make as much as $836 million in peak sales from the drug. Due to its niche nature in treating NTRK gene fusion cancer, no comparable standard of care exists that Vitrakvi can be tested against. Its current price tag comes in at $19,600 for a 30-day supply.

Health regulators in North America have been more accepting of the drug. The Food and Drug Administration (FDA) approved Vitraki in November 2018, while Health Canada approved Bayer's drug in July 2019.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.